The effect of obstructive sleep apnea severity on PTSD symptoms during the course of esketamine treatment: a retrospective clinical study

• DOI: 10.5664/jcsm.10746
• Publication Date: 2023-08-04T19:00:18Z
• Authors: Madison K. Titone; Christopher Hunt; Andrew Bismark; Brandon Nokes; Ellen Lee; Dhakshin Ramanathan; Jane Park; Peter Colvonen
• Keywords: Depression; Veterans Affairs

Intranasal administration of esketamine is Food and Drug Administration-approved for treatment-resistant depression. In a recent retrospective case series, we show that it has promise in reducing symptoms posttraumatic stress disorder (PTSD) as well. Untreated obstructive sleep apnea (OSA) prevalent among veterans with PTSD been shown to interfere other treatments. the current study, examined whether OSA impacts esketamine's effectiveness or